Liraglutide Increases Heart Rate in T2DM With Stable CAD

Share this content:
Liraglutide Increases Heart Rate in T2DM With Stable CAD
Liraglutide Increases Heart Rate in T2DM With Stable CAD

TUESDAY, Oct. 25, 2016 (HealthDay News) -- Liraglutide increases heart rate (HR) and reduces heart rate variability (HRV) in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD), according to a study published online Oct. 19 in Diabetes Care.

Preman Kumarathurai, M.D., from the Copenhagen University Hospital of Bispebjerg in Denmark, and colleagues administered liraglutide or placebo to a backbone therapy of metformin. As a measure of HRV, the standard deviation of beat-to-beat (SDNN) intervals was assessed by 24-hour Holter monitoring. The authors also assessed diurnal HRV and sympathovagal balance analyzed by root mean square of successive differences (RMSSD) in NN intervals and high frequency (HF) and low-frequency (LF) power.

The researchers found that, compared with placebo, liraglutide decreased SDNN in 27 subjects; decreased RMSSD; and increased the mean, daytime, and nighttime HR. After adjustment for metabolic and HR changes, the decrease in SDNN remained significant. Liraglutide also correlated with a reduction in HF power, without affecting the LF/HF ratio.

"In overweight patients with CAD and newly diagnosed T2D, liraglutide increased HR and reduced HRV despite significant weight loss and improvement in metabolic parameters," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which manufactures liraglutide and funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Deaths, Cardiac Arrest Not Rare in Triathlon Participants

Deaths, Cardiac Arrest Not Rare in Triathlon Participants

Incidence of death or cardiac arrest 1.74 per 100,000 participants; higher incidence in men, with age

ACP Does Not Support Legalization of Assisted Suicide

ACP Does Not Support Legalization of Assisted Suicide

Legalization would affect trust in the patient-physician relationship, and in the medical profession

AAP: Epinephrine Admin Training Needed in Many Schools

AAP: Epinephrine Admin Training Needed in Many Schools

In 2015 to 2016, 2.7 percent reported that epinephrine was administered by unlicensed staff

is free, fast, and customized just for you!

Already a member?

Sign In Now »